+Compare
ADTX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
1.57M

ADTX Aditxt Forecast, Technical & Fundamental Analysis

a life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ADTX with price predictions
07:00 PM EST Dec 05, 2023

Momentum Indicator for ADTX turns negative, indicating new downward trend

ADTX saw its Momentum Indicator move below the 0 level on December 05, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 63 similar instances where the indicator turned negative. In of the 63 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ADTX entered a downward trend on December 01, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ADTX's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ADTX just turned positive on November 14, 2023. Looking at past instances where ADTX's MACD turned positive, the stock continued to rise in of 24 cases over the following month. The odds of a continued upward trend are .

ADTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.395) is normal, around the industry mean (20.710). P/E Ratio (0.000) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.674) is also within normal values, averaging (330.425).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ADTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 27%. IVBT experienced the highest price growth at 1,413%, while IBIO experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

ADTX is expected to report earnings to rise 4,058.27% to -11559 cents per share on August 30

Aditxt ADTX Stock Earnings Reports
Q2'23
Est.
$-115.60
Q1'23
Est.
$-2.78
Q4'22
Missed
by $0.48
Q3'22
Est.
$-3.89
Q2'22
Est.
$-6.50
The last earnings report on May 31 showed earnings per share of -277 cents, meeting the estimate of -277 cents. With 150.60K shares outstanding, the current market capitalization sits at 1.57M.
A.I. Advisor
published General Information

General Information

a life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
737 North Fifth Street
Phone
+1 650 870-1200
Employees
61
Web
https://www.aditxt.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INFA27.391.36
+5.22%
Informatica
GNSS1.650.01
+0.61%
Genasys
FBK35.700.06
+0.17%
FB Financial Corp
BIOL1.23-0.06
-4.65%
Biolase
GHG3.40-0.20
-5.56%
GreenTree Hospitality Group Ltd

ADTX and

Correlation & Price change

A.I.dvisor tells us that ADTX and ORMP have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ADTX and ORMP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADTX
1D Price
Change %
ADTX100%
-2.31%
ORMP - ADTX
32%
Poorly correlated
+3.30%
NRBO - ADTX
31%
Poorly correlated
+3.58%
BLRX - ADTX
29%
Poorly correlated
+4.43%
AEZS - ADTX
28%
Poorly correlated
+6.41%
XTLB - ADTX
27%
Poorly correlated
-7.08%
More

Groups containing ADTX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADTX
1D Price
Change %
ADTX100%
-2.31%
dna
(undefined stocks)
99%
Closely correlated
+5.28%
immunotherapy
(undefined stocks)
83%
Closely correlated
+1.81%
therapeutics
(undefined stocks)
25%
Poorly correlated
+1.72%